PEP-223/CoVaccine HT(Pepscan Therapeutics)(PEP-223/CoVaccine HT(Pepscan Therapeutics))

概要

基本信息

药物类型

治疗性疫苗

别名-

靶点-

作用机制

免疫刺激剂

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症-

非在研适应症

前列腺癌

原研机构

Pepscan Holding NV

在研机构-

非在研机构

Pepscan Holding NV

最高研发阶段无进展临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 PEP-223/CoVaccine HT(Pepscan Therapeutics) 相关的临床试验

NCT00895466 / Unknown status临床1/2期

A Phase I-II Open Label Clinical Trial, Evaluating the Efficacy and Safety of Administration of the Therapeutic Vaccine PEP-223/CoVaccine HT, to Hormone Treatment naïve, Immunocompetent Subjects With T1-3, N0-1/x, M0 Prostate Cancer, Eligible for Hormone Therapy.

The purpose of this trial is to investigate whether treatment with this new drug will result in lower testosterone levels in men with prostate cancer. At the same time it will be investigated whether the drug induces side effects, and if so, which ones.

开始日期2008-10-01

申办/合作机构

Pepscan Therapeutics BV

[+1]

100 项与 PEP-223/CoVaccine HT(Pepscan Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 PEP-223/CoVaccine HT(Pepscan Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 PEP-223/CoVaccine HT(Pepscan Therapeutics) 相关的专利（医药）

登录后查看更多信息

100 项与 PEP-223/CoVaccine HT(Pepscan Therapeutics) 相关的药物交易

登录后查看更多信息